David Einhorn
Greenlight Capital
David Einhorn Filana Therapeutics, Inc stake
total: 357
Greenlight Capital FLNA trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2021 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2022 Q1
According to 2026 Q2 report, David Einhorn doesn't hold any Filana Therapeutics, Inc (FLNA) shares. To date, the estimated cost basis is nearly $43.7 for "buy" trades and estimated average "sell" price is $43.7. Greenlight Capital first purchased FLNA in 2021 Q4, initially acquiring 40,620 shares. Since the initial investment in Filana Therapeutics, Inc (FLNA), Greenlight Capital has made 1 more transaction.
When did David Einhorn sell Filana Therapeutics, Inc (FLNA)?
David Einhorn sold off the entire Filana Therapeutics, Inc (FLNA) position in 2022 Q1.
When did David Einhorn buy Filana Therapeutics, Inc (FLNA)?
David Einhorn first invested in Filana Therapeutics, Inc (FLNA) in 2021 Q4 at the reported quarter-end price of $43.70 per share.
What's the cost basis of Greenlight Capital's FLNA stake?
The estimated cost basis for Filana Therapeutics, Inc (FLNA) stake is around $43.70 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $43.70
- Weighted AVG sell price:
- $43.70
David Einhorn's historical trades in Filana Therapeutics, Inc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q1
|
0.00%
|
0
|
$43.70
|
|
-100% (-40,620)
|
-0.11%
|
|
2021 Q4
|
0.11%
|
40,620
|
$43.70
|
$1,775,000
|
new
|
+0.11%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.